DPP4 and Hypoglycemia: Compared with glipizide, the DPP-4 inhibitor reduced the incidence of severe hypoglycemia in dialysis patients significantly (five of 64 participants vs. 0 of 64, respectively) but not in non-dialysis patients (six cases of 212 participants vs. three cases of 210 participants).